Toxic erythema of chemotherapy (TEC) is a unifying term for the broad spectrum of cutaneous dose-dependent cytotoxic reactions that may occur with receipt of chemotherapeutic agents.
1 In acute cases of TEC, patients can develop severe erythema, pain, swelling, and/or blistering, which may require inpatient management. However, therapeutic options for TEC are limited. Chemotherapy cessation, delay, or dose modification are the only reliable methods of resolving TEC. Supportive agents, such as high-potency topical corticosteroids, topical keratolytics, wound care, and pain control, have a variable response. These agents are associated with relatively slow improvement, involving 2 to 4 weeks of recovery after chemotherapy interuption.
1